Physician profile
Ali Latefi
NPI 1215972732
$5,072.89
in general payments reported to CMS, 2019-2025
28 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $3,030 · 2021: $307 · 2022: $135 · 2023: $185 · 2024: $399 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,016.55 | 2019-2020 | |
| Boston Scientific Corporation | $352.96 | 2019-2024 | Watchman Flx, Tria Firm |
| Procept Biorobotics Corporation | $238.27 | 2024-2025 | Aquabeam System |
| Ferring Pharmaceuticals INC. | $121.56 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $117.64 | 2023-2025 | Speedicath |
| Abbvie INC. | $109.93 | 2023-2025 | |
| Bard Access Systems, INC. | $102.54 | 2019 | |
| Varian Medical Systems, INC. | $93.89 | 2021 | |
| Healthtronics Stone Solutions, LLC | $93.89 | 2021 | |
| Urogen Pharma, INC. | $87.60 | 2024-2025 | |
| Janssen Biotech, INC. | $86.09 | 2023-2025 | Erleada |
| Endo USA, INC. | $77.55 | 2025 | Aveed, Xiaflex |
| Progenics Pharmaceuticals, INC. | $69.69 | 2024-2025 | |
| Medtronic, INC. | $64.31 | 2022-2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $62.34 | 2024-2025 | Provenge |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.07 | 2025 | Xtandi |
| Olympus America INC. | $46.93 | 2023-2025 | Itind System |
| Convatec INC. | $41.97 | 2024 | |
| Pfizer INC. | $39.61 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $39.50 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Conmed Corporation | $28.23 | 2019 | |
| Tolmar, INC. | $24.73 | 2025 | Jatenzo, Eligard |
| E.R. Squibb & Sons, L.L.C. | $21.58 | 2025 | Opdivo |
| Antares Pharma, INC. | $18.41 | 2024 | Xyosted |
| Blue Earth Diagnostics | $17.33 | 2024 | |
| Sumitomo Pharma America, INC. | $14.49 | 2025 | Gemtesa |
| Laborie Medical Technologies Corp. | $13.20 | 2025 | |
| Axonics, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Latefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.